Table of Content

25 October 2022, Volume 14 Issue 5 Previous Issue    Next Issue

Select

Building a basic project to serve the innovation and transformation of new tumor markers—Practice and effectiveness of the Tumor marker committee of Chinese anti⁃cancer association ZHOU Feng, HUANG Qichao, GUO Xu, CHENG Qingqing, CUI Yaqiong, ZHAO Jianhua, ZHANG Yanhui, WANG Yu, CUI Yue, LIANG Ting, WANG Min, YANG Qiongyao, ZHENG Peng, KANG Ting, PANG Shuo, 2022, 14 (5):  480-483.  doi: 10.3969/j.issn.1674-5671.2022.05.01 Abstract ( 2972 )   PDF   Save Related Articles | Metrics

Select

Research progress of targeted therapy and immunotherapy in preo⁃perative neoadjuvant therapy and postoperative adjuvant therapy for hepatocellular carcinoma ZHU Chengpei, ZHAO Haitao 2022, 14 (5):  484-490.  doi: 10.3969/j.issn.1674-5671.2022.05.02 Abstract ( 2768 )   PDF   Save Related Articles | Metrics

Select

Research progress of drug therapy for gastroenteropancreatic neuroendocrine cancer LIANG Yun, JI Shunrong, YU Xianjun, CHEN Jie 2022, 14 (5):  491-495.  doi: 10.3969/j.issn.1674-5671.2022.05.03 Abstract ( 2983 )   PDF   Save Related Articles | Metrics

Select

miR⁃29a⁃3p inhibits the proliferation and invasion of kidney renal clear cell carcinoma by regulating the expression of KDM5B QIU Haijun, LI Yuming, HU Jinpeng 2022, 14 (5):  496-502.  doi: 10.3969/j.issn.1674?5671.2022.05.04 Abstract ( 95 )   PDF   Save Objective To investigate the effect of miR?29a?3p on the proliferation and invasion of kidney renal clear cell carcinoma (KIRC) by regulating the expression of lysine?specific demethylase 5B (KDM5B) and its clinical significance. Methods The expression of KDM5B in patients with different KIRC stages and its impact on the prognosis and survival of KIRC were analyzed by using TCGA database. TCGA data were used to analyze the expression of miR?29a?3p in patients with different KIRC stages and its correlation with KDM5B. The miR?29a?3p mimics, mimics?NC and miR?29a?3p inhibitor, denoted by miR?29a mimic group, mimics NC group and inhibitor group, respectively, were transfected into KIRC 786?O and Caki?1 cells, respectively, by liposome transfection technology. The expre?ssion levels of miR?29a?3p and KDM5B were detected by RT?qPCR. The cell proliferation ability was detected by MTS, and the cell invasion ability was detected by transwell. Dual luciferase reporter assay was used to verify the targeting relationship between miR?29a?3p and KDM5B. Results TCGA database analysis showed that the expression of KDM5B differed most among the patients with different KIRC stages, which were significantly affected the prognosis of KIRC patients (HR=2.882, P<0.001). The expression of miR?29a?3p bound to KDM5B was most different among the patients with different KIRC stages (P<0.001), and had the strongest correlation with KDM5B (r=-0.283, P<0.001). Dual luciferase reporter assay confirmed that miR?29a?3p was specifically bound to KDM5B. After overexpression of miR?29a?3p, the expression level of KDM5B was down?regulated in 786?O and Caki?1 cells, and the cell proliferation ability and the number of transmembrane cells were decreased (all P<0.05). After miR?29a?3p silencing, the expression level of KDM5B was up?regulated, and the cell proliferation ability and the number of transmembrane cells were increased (all P<0.05). Conclusions miR?29a?3p may inhibit the proliferation and invasion of KIRC cell lines 786?O and Caki?1 by inhibiting the expression of H3K4 demethylase KDM5B. Related Articles | Metrics

Select

Effect of combining anlotinib with gefitinib on proliferation of non⁃small cell lung cancer PC9/GR cells and its possible mechanism WU Min, JIN Mengmeng, CAO Xiaohui, Li Yonghuai 2022, 14 (5):  503-508.  doi: 10.3969/j.issn.1674-5671.2022.05.05 Abstract ( 3801 )   PDF   Save Objective To investigate the effect of combining anlotinib with gefitinib on the proliferation of gefitinib-resistant human non-small cell lung cancer (NSCLC) PC9/GR cells and its possible mechanism. Methods The PC9/GR cells were divided into anlotinib group, gefitinib group, anlotinib combined with gefitinib group and control group, respectively, according to different drug administrations. MTT assay was used to detect the cell proliferation. Flow cytometry was used to analyze the distribution of cell cycle. The protein expression levels of p-ERK1/2 and p-AKT were detected by Western blot. Results The half inhibitory concentrations (IC50) of anlotinib and gefitinib in PC9/GR cells for 72 h were (1.91±0.18) μmol/L and (4.83±0.15) μmol/L, respectively. Both drugs showed anti-proliferation effects of dose-dependent, and the combination of the two drugs showed obvious synergistic effects, with a combination index (CI) less than 1. The anlotinib and gefitinib could arrest PC9/GR cells at G0/G1 phase (all P<0.05). Compared with the single drug group, the G0/G1 phase arrest in the combination group wer more significant, significantly down-regulating the protein expression of p-ERK1/2 and p-AKT (all P<0.05). Conclusions The anlotinib combined with gefitinib has synergistic anti-proliferation effect on non-small cell lung cancer PC9/GR cells, and can improve the sensitivity of gefitinib. The synergistic anti-tumor mechanism may be related to the induction of cell cycle arrest and down-regulation of p-ERK1/2 and p-AKT protein expressions. Related Articles | Metrics

Select

miR⁃203a⁃3p regulates the biological behavior of hepatoma cells by targeting LASP1 mediates Akt/GSK⁃3β/Snail signaling pathway DONG Xiang, DONG Meng, SHI Xiaoxiao, YU Ruohui, SU Junjun 2022, 14 (5):  508-514.  doi: 10.3969/j.issn.1674-5671.2022.05.06 Abstract ( 2740 )   PDF   Save Objective To investigate the effect of miR?203a?3p on the biological behavior of hepatocellular carcinoma (HCC) cells and its related molecular mechanism. Methods The miR?203a?3p mimics (miR?203a?3p mimics), negative control (miR?NC mimics), LIM and SH3 protein 1 (LASP1) overexpression plasmid (pcDNS?LASP1) and negative control plasmid (pcDNA?NC) were transfected into HepG2 cells. The expressions of miR?203a?3p and LASP1 mRNA were detected by qRT?PCR; cell proliferation was detected by the CCK?8 method and the allogeneic transplantation experiment; cell migration ability was detected by Wound healing assay; cell invasion ability was detected by Transwell; cell apoptosis was detected by Annexin V?FITC / PI method; Double luciferase reporter was used to detect the targeting relationship between miR?203a?3p and LASP1; Western blot was used to detect the protein expressions of LASP1, protein kinase B (Akt), phosphorylated Akt (p?Akt), glycogen synthase kinase?3β (GSK?3β), phosphorylated GSK?3β (p?GSK?3β) and Snail. Results Compared with those in the miR?NC group, the proliferation activity, migration rate, invasion number, LASP1 mRNA and protein expressions, the ratio of p?Akt/Akt and p?GSK?3β/GSK?3β, and the protein expression of Snail of HepG2 cells in the miR?203a?3p group were significantly decreased; the volume and mass of transplanted tumor in mice were significantly decreased;  the apoptosis rate was significantly increased (all P<0.01). Targetscan software prediction showed that miR?203a?3p had a targeting relationship with LASP1. Compared with that of LASP1?Wt+miR?NC group, the relative luciferase activity of LASP1?Wt+miR?203a?3p group was significantly decreased (P<0.001). Compared with those of the miR?203a?3p+pcDNA?NC group, the proliferation activity, migration rate, invasion number, p?Akt/Akt and p?GSK?3 β/GSK?3 β ratio, the protein expression of Snail protein of HepG2 cells in the miR?203a?3p+LASP1 group were significantly increased; the volume and mass of transplanted tumor in mice were also significantly increased; the apoptosis rate was significantly decreased (all P<0.01). Conclusions The miR?203a?3p may regulate the activity of Akt/GSK?3β/Snail signaling pathway by targeting the inhibition of LASP1 expression, thereby regulating the biological behavior of HCC cells. Related Articles | Metrics

Select

Incidence and mortality of stomach cancer in registration areas of Yunnan in 2016 and its trends from 2012 to 2016 ZHU Yunfang, XU Wen, XIAO Yize, WEN Hongmei, CHEN Yang, SHI Qingping, REN Siying, CHENG Huirong, ZHU Linfang 2022, 14 (5):  515-520.  doi: 10.3969/j.issn.1674?5671.2022.05.07 Abstract ( 114 )   PDF   Save Objective To analyze the incidence and mortality of stomach cancer in registration areas of Yunnan in 2016 and its trend from 2012 to 2016, and to provide a reference for the prevention and control of stomach cancer. Methods The data of stomach cancer from 2012 to 2016 in registration areas of Yunnan were collected, and the incidence, mortality, age-standardized rate, cumulative rate (0-74 years old) and truncated age-standardized rate (TASR) (35-64 years old) of stomach cancer were calculated. Joinpoint 4.9 was used to calculate the annual percentage change (APC) of stomach cancer incidence and mortality in registration areas of Yunnan from 2012 to 2016. Results In 2016, the crude incidence of stomach cancer in registration areas of Yunnan was 14.10/105, the China age-standardized rate by Chinese standard population (ASR China) was 9.63/105, the cumulative rate (0-74 years old) was 1.17%, and the TASR (35-64 years old) was 16.76/105, accounting for 6.62% and ranking the 6th in the incidence of all malignant tumors. The crude mortality in registration areas of Yunnan was 11.29/105, the ASR China was 7.41/105, the cumulative rate (0-74 years old) was 0.85%, and the TASR (35-64 years old) was 11.67/105, accounting for 8.87% and ranking the 4th in the mortality of all malignant tumor deaths. The incidence and mortality of stomach cancer in males were higher than those of females, and higher in rural areas than in urban areas. The incidence of stomach cancer increased rapidly after the age of 30 years, and reached the peak in the age group of 75-80 years, The mortality increased rapidly after the age of 35 years, reached the peak in the age group of 85+ years. From 2012 to 2016, the incidence of stomach cancer in the registration areas of Yunnan showed an upward trend (APC=6.10%, P=0.015); the mortality rate increased slowly without significant difference (APC=6.50%, P=0.103) . Conclusions In 2016, the incidence and mortality of stomach cancer in registration areas of Yunnan were lower than the averages of China, with higher rates in males (or in rural areas) than in females (or in urban areas). From 2012 to 2016, the incidence of stomach cancer showed an increasing trend, and the mortality trend was stable. In the future, the prevention and control of stomach cancer should be further strengthened. Related Articles | Metrics

Select

Efficacy and safety of Regorafenib combined with PD⁃1 inhibitors in advanced microsatellite stable colorectal carcinoma LUO Xixi, CHEN Jiamei, SHI Wei, CHEN Yongshun 2022, 14 (5):  521-528.  doi: 10.3969/j.issn.1674?5671.2022.05.08 Abstract ( 122 )   PDF   Save Objective To evaluate the efficacy and safety of Regorafenib combined with PD?1 inhibitors for the third?line or above treatment of advanced microsatellite stable (MSS) colorectal cancer (CRC). Methods A total of 22 patients with advanced MSS CRC, who received Regorafenib combined with PD?1 inhibitors or Regorafenib monotherapy for third?line or above treatment in Renmin Hospital of Wuhan University from January 2019 to March 2022, were selected as the research objects, including 10 patients in the combination therapy group and 12 patients in the Regorafenib monotherapy group. The progression?free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and incidence of adverse events (AEs) were compared between the two groups. Results Kaplan?Meier survival analysis showed that there was no significant difference in median OS between the combination therapy group and the monotherapy group (6.10 months vs 6.13 months, P=0.827). However, the combination therapy group had better median PFS than the monotherapy group (4.00 months vs 1.63 months, P=0.025), and the DCR in combination therapy group were also better than the monotherapy group, though there was no statistical significance (70.0% vs 25.0%, P=0.084). No grade 4 or higher AEs were observed in either group. The overall incidence of AEs (100.0% vs 91.7%) and the incidence of grade ≥3 AEs (30.0% vs 25.0%) were not statistically different between the combination therapy group and the monotherapy group (all P>0.05). Conclusions  Compared with Regorafenib monotherapy, Regorafenib combined with PD?1 inhibitors as the third?line or above treatment regimen for advanced MSS CRC may bring benefits for PFS, and it is worthy of further clinical trials. Related Articles | Metrics

Select

Combination of Venetoclax, Azacitidine and Chidamide in treating refractory and relapsed acute myeloid leukemia: six cases reports and literature review FU Qiang, WANG Huifang, LIU Kaiyan, HUANG Xiaojun, TANG Feifei 2022, 14 (5):  528-533.  doi: 10.3969/j.issn.1674-5671.2022.05.09 Abstract ( 2812 )   PDF   Save Objective To investigate the clinical efficacy and safety of Venetoclax combined with Azacitidine and Chidamide in treating the patients with refractory and relapsed acute myeloid leukemia (R/R AML). Methods The efficacy and safety of Venetoclax combined with Azacitidine and Chidamide for 6 R/R AML patients treated in the Department of Hematology, Peking University People's Hospital, from March 15, 2021 to November 30, 2021, were retrospectively analyzed. The steady-state trough concentrations (Cmin) of Venetoclax at different times during the induction period (day 7, 14, 21 and 28) were monitored and counted. Results Among the 6 R/R AML patients, 3 patients showed clinical response, including 2 complete remission (CR) and 1 CR with incomplete hematological recovery (CRi). The median follow-up time was 178 days. There were 5 patients currently alive, with an overall survival (OS) rate of 83.3%(5/6). The steady-state Cmin of Venetoclax on day 7, 14, 21 and 28 were (3 181.67±1 631.90) ng/mL, (2 688.67±1 926.36) ng/mL, (2 142.17±1 380.35) ng/mL, (2 766.67±1 138.55) ng/mL, respectively. Conclusions Venetoclax combined with Azacitidine and Chidamide can improve the clinical efficacy in R/R AML patients, and such a combination is expected to be one of the feasible options for the salvage therapy of R/R AML patients. Related Articles | Metrics

Select

Contrast enhanced ultrasound combined with immunohistochemistry in the diagnosis of microvascular invasion of small hepatocellular carcinoma: a retrospective study in two hospitals WANG Feiqian, NUMATA Kazushi, RUAN Litao, NAKANO Masayuki, BAI Xiaoxu, LIU Yuxin, QU Kai 2022, 14 (5):  534-540.  doi: 10.3969/j.issn.1674-5671.2022.05.10 Abstract ( 2730 )   PDF   Save Objective To investigate the value of the contrast enhanced ultrasound (CEUS) combined with immunohistochemistry (IHC) in preoperative diagnosis of microvascular invasion (MVI) of small hepatocellular carcinoma (HCC). Methods The data of 142 HCC patients, including 177 newly developed HCC lesions with a maximum diameter of no more than 3 cm were retrospectively collected from the Yokohama City University Medical Center of Japan and the First Affiliated Hospital of Xi'an Jiaotong University. According to the pathological diagnosis, the patients were divided into MVI (+) group (n=37) and MVI (-) group (n=140). Preoperative CEUS arterial phase (AP) and post-vascular phase (PVP) images were used to observe whether there was hypervascularity and hypovascularity around the lesion. The expressions of heat shock protein 70 (HSP70) and glypican 3 (GPC3) in preoperative biopsy samples were detected by IHC method. Results When all CEUS indicators (AP, PVP) and IHC indicators (GPC3, HSP70) were diagnosed MVI individually, PVP had the highest diagnostic efficiency, with an accuracy of 91.0% and an area under the curve (AUC) of 0.893. The diagnostic efficiency of GPC3 combined with HSP70 (accuracy: 79.8%, AUC: 0.790) was better than that of GPC3 alone (accuracy: 69.5%, AUC: 0.752) or HSP70 alone (accuracy: 60.7%, AUC: 0.701). The combined diagnosis of PVP+GPC3+HSP70 had the best diagnostic efficiency, with a specificity of 98.5%, an accuracy of 92.5%, and an AUC of 0.840. Conclusions Observing the PVP of CEUS and using IHC to detect the expressions of GPC3 and HSP70 can better diagnose the MVI of small HCC preoperatively. Related Articles | Metrics

Select

Retrospective analysis of efficacy and prognosis of newly diagnosed multiple myeloma patients with 1q21 amplification CHEN Xiaolei, ZHANG Yong, ZHANG Yue, LI Jie, ZHOU Hebing 2022, 14 (5):  541-547.  doi: 10.3969/j.issn.1674-5671.2022.05.11 Abstract ( 3207 )   PDF   Save Objective To investigate the relationship between 1q21 amplification (1q21+) and the treatment efficacy and prognosis of the newly diagnosed multiple myeloma (NDMM) patients, and to explore the advantage of 1q21+ in the risk stratification of MM. Methods The patients with NDMM treated in Beijing Lu-He Hospital, Capital Medical University, from November 2015 to November 2021 were selected as the research objects. The cytogenetic abnormalities were detected by the interphase fluorescence in situ hybridization (iFISH). The relationship between 1q21+ and the efficacy and prognosis of bortezomib based induction chemotherapy and autologous stem cell transplant (ASCT) were analyzed. The stratification advantages of MM R2-ISS and R-ISS were compared. Results A total of 159 NDMM patients were included in this study, 79 patients with 1q21+ and 80 patients with no 1q21+, of whom 41 patients were treated with RVD regimens and 118 patients with no-RVD regimens. Among 1q21+ patients, the complete remission (CR) rate of the RVD group was higher than that of the no-RVD group (P<0.001). In RVD group, the CR rate of 1q21+ patients was lower than that of no 1q21+ patients (P=0.004). Multivariable analysis showed that 1q21+ was an independent risk factor for the progression-free survival (PFS) and the overall survival (OS) in the patients with NDMM (P<0.05). Among the 50 patients receiving ASCT, the 1-year and 3-year OS and PFS rates of 1q21+ patients were shorter than those of no 1q21+ patients (P=0.055, 0.002). The 1-year PFS rates of patients with stageⅠ, Ⅱ,Ⅲ and Ⅳ of R2-ISS were 96.3%, 95.0%, 92.0% and 85.4%, respectively, and the 3-year PFS rates were 88.9%, 80.5%, 74.0% and 61.5%, respectively, with statistical significance (P=0.005). Conclusions 1q21+ is an independent risk factor for the OS and PFS in the patients with NDMM, which is associated with poor prognosis. RVD can improve the remission depth of 1q21+ NDMM patients, while ASCT can improve the prognosis of patients, but neither of them can completely overcome the adverse effects of 1q21+. Clinically, the R2-ISS has advantages in the MM risk stratification. Related Articles | Metrics

Select

Comparison of efficacy between cold and hot snare polypectomy for 4-9 mm colorectal polyps JI Qiunan, ZHANG Jishun, YUAN Zhifang, DUAN Zhuoyang, SHANG Zhanmin 2022, 14 (5):  547-551.  doi: 10.3969/j.issn.1674-5671.2022.05.12 Abstract ( 2914 )   PDF   Save Objective To compare the efficacy between the cold snare polypectomy (CSP) and hot snare polypectomy (HSP) for 4-9 mm colorectal polyps. Methods A total of 187 patients who underwent polypectomy in  the Department of Gastroenterology of Beijing Chao-yang Hospital from June 2021 to November 2021 were selected as research subjects, included 284 polyps, among which 145 were treated with CSP and 139 were treated with HSP. The primary study endpoint was the complete resection rate, and the secondary study endpoints included polyp retrieval rate, polypectomy time, the cost of polypectomy and length of hospital stays. The complications included immediate bleeding, delayed bleeding and perforation. Results  The complete resection rate in CSP group and HSP group were 90.34% and 92.09%(P=0.336), respectively. The immediate bleeding occurred in 7 cases in the CSP group and 5 cases in the HSP group, and there was no significant difference between the two groups (P=0.606). There was 1 case of late bleeding in the CSP group and none in the HSP group. Perforation did not occur in either group. All specimens obtained after polypectomy were successfully recovered. The procedure time of the CSP group was shorter than that of the HSP group (70.6 s vs 75.2 s, P<0.001). The average cost in the CSP group was lower than that in the HSP group (￥1 371.00 vs ￥2 434.90, P<0.001). The average length of hospital stays in the CSP group was shorter than that in the HSP group (2.9 d vs 3.6 d, P<0.001). Conclusions Both CSP and HSP are safe and effective treatment methods for the 4-9 mm colorectal polyps. However, CSP is more time-saving with less cost and shorter hospital stays. Related Articles | Metrics

Select

A prospective cohort study on the effect of circadian clock rhythm related factors on female HPV negative conversion WANG Fuyuan, WANG Zhaoxia, ZHAO Le, XIN Liqing, HE Simin, WANG Tong 2022, 14 (5):  552-557.  doi: 10.3969/j.issn.1674?5671.2022.05.13 Abstract ( 124 )   PDF   Save Objective To investigate the epidemiologic factors influencing the negative conversion after human papilloma virus (HPV) infection. Methods The data of 511 patients with HPV infection treated in the First Hospital of Shanxi Medical University from January 2020 to February 2020 were collected, and the factors influencing the negative conversion after HPV infection were analyzed by using univariable and multifactorial logistic regression. Results Among 511 patients with HPV infection, 244 (47.75%) patients showed negative conversion after HPV infection (conversion group) and 267 (52.25%) patients showed persistent infection (non-conversion group). The results of sleep assessment showed that the overall sleep status of all enrolled patients was poor, with an average SRSS score of (26.23±5.75) point, in which the contributions of physiological and psychological reaction after insomnia, insufficient sleep time and difficulty in falling asleep were higher than other factors. Univariable analysis showed that the key factors including circadian rhythm (age, sleep quality, anxiety state), sexual frequency, pregnancy time and work status were associated with negative conversion after HPV infection(all P<0.05). In the conversion group, 61.07% (149/244) of the patients reported poor recent sleep quality, while 81.27% (217/267) of the patients in the non-conversion group reported poor recent sleep quality. The difference between the two groups was statistically significant (P<0.001). Multivariable logistic regression showed that recent sleep quality and drug intervention were independent influencing factors of negative conversion after HPV infection. Good recent sleep quality was a protective factor of negative conversion after HPV infection, and the probability of negative conversion after HPV infection in patients with good sleep quality was 1.861 times higher (OR=2.861, 95%CI: 1.735-4.715). In terms of pharmacological interventions, the application of rebacin (OR=0.444, 95%CI: 0.299-0.662) or interferon (OR=0.080, 95%CI: 0.031-0.206) was more conducive to the negative conversion after HPV infection, and the rebacin was more effective. Conclusions Patients with HPV infection generally have poor recent sleep quality. The key factors of circadian rhythm such as sleep quality and anxiety can affect the negative conversion after HPV infection, and improving recent sleep quality and proper mental guidance can help clear the HPV in the infected people. Related Articles | Metrics

Select

Status and influencing factors of sexual dysfunction in young breast cancer patients during endocrine therapy GAN Lu, FANG Qiong 2022, 14 (5):  558-564.  doi: 10.3969/j.issn.1674?5671.2022.05.14 Abstract ( 152 )   PDF   Save Objective To analyze the current occurrence and influencing factors of female sexual dysfunction (FSD) in young breast cancer patients during endocrine therapy. Methods A total of 189 young female breast cancer patients who underwent posto-perative adjuvant endocrine therapy in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from January 2021 to July 2021 were selected as the research subjects. The general information questionnaire, female sexual function index scale (FSFI), body image scale for breast cancer patients (BIS), hospital anxiety and depression scale (HADS), social science research solutions (SSRS) and the revised dyadic adjustment scale (RDAS) were collected and analyzed. Logistic regression was used to analyze the influencing factors of FSD. Results Among 189 young female breast cancer patients, the incidence of FSD was 81.0% (153/189). Multivariable analysis showed that breast reconstruction reduced the risk of FSD, compared with mastectomy (OR=0.243, 95%CI: 0.076-0.779, P=0.017). Posto-perative BIS score≥8 was a protective factor for FSD (OR=0.176, 95%CI: 0.059-0.526,P=0.002). Previous chemotherapy (OR=5.250, 95%CI: 2.065-13.347, P<0.001) and anxiety (OR=6.348, 95%CI: 1.985-20.299, P=0.002) were independent risk factors for FSD. Conclusions Young female breast cancer patients have a higher incidence of FSD during endocrine therapy, especially in the patients who have been treated with chemotherapy, have anxiety disorders and poor body image. It is necessary to pay attention to patients' sexual health issues and strengthen the assessment of patients' sexual function by carrying out targeted intervention. Related Articles | Metrics

Select

Role and mechanism of non⁃coding RNA on EGFR and related signaling pathways in tumors NIE Shihao, LIU Hao, LU Yuanyuan 2022, 14 (5):  564-568.  doi: 10.3969/j.issn.1674?5671.2022.05.15 Abstract ( 106 )   PDF   Save Related Articles | Metrics

Select

Research progress of rhythm gene NPAS2 in tumors CHEN Yafan, WANG Gang, TIAN Yiyuan, TONG Hongwei, YUAN Peng 2022, 14 (5):  569-574.  doi: 10.3969/j.issn.1674?5671.2022.05.16 Abstract ( 139 )   PDF   Save Related Articles | Metrics

Select

Research progress of cytokine release syndrome due to tumor immunotherapy LIU Yan, JIA Yuxian, LI Tingting 2022, 14 (5):  575-580.  doi: 10.3969/j.issn.1674?5671.2022.05.17 Abstract ( 114 )   PDF   Save Related Articles | Metrics

Select

Research progress on the association between microbiota and breast cancer ZHENG Yaqi, QIN Zihan, SHENG Shiying, YANG Zhuangqing 2022, 14 (5):  581-585.  doi: 10.3969/j.issn.1674?5671.2022.05.18 Abstract ( 94 )   PDF   Save Related Articles | Metrics

Select

Research progress of Netrins and its receptors in malignant tumors GAO Xing, YE Jiazhou, LU Lu, LI Yongqiang, LIN Yan, LIANG Rong 2022, 14 (5):  586-592.  doi: 10.3969/j.issn.1674-5671.2022.05.19 Abstract ( 130 )   PDF   Save Related Articles | Metrics

Select

Advances in clinical treatment of advanced large cell neuroendocrine carcinoma of the lung LYU Tianyuan, ZHANG Xinfeng, WANG Huaizhang, TANG Yujun, SU Shanshan, WANG Cuicui 2022, 14 (5):  593-599.  doi: 10.3969/j.issn.1674?5671.2022.05.20 Abstract ( 93 )   PDF   Save Related Articles | Metrics